Gland Pharma Limited (Gland), a generic injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) filed for olopatadine hydrochloride ophthalmic solution USP, 0.7% (OTC).
The product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief 0.7%, marketed by Alcon Laboratories Inc. It is indicated for the treatment of ocular itching associated with allergic conjunctivitis, offering patients an effective over-the-counter option for relief from allergy-related eye symptoms.
Also read: Q2 Results Highlights: 3M India profit jumps 43%; Titan revenue up 25%, tops estimates
Gland Pharma has strengthened its position in the ophthalmic segment with this approval, which allows the company to market a therapeutically equivalent product in the highly regulated US market. This milestone underscores Gland’s focus on developing high-quality ophthalmic formulations and expanding its presence in the global pharmaceutical sector.
Following the announcement, Gland Pharma’s shares closed at ₹1,710 on the NSE today, January 7, up ₹16.70 or 0.99%.
Also read: Gland Pharma Q2 net profit up 12% to ₹184 crore on higher revenue, R&D, new US launches
